Bayforest Capital Ltd Acquires 18,434 Shares of DENTSPLY SIRONA Inc. $XRAY

Key Points

• Bayforest Capital Ltd has increased its stake in DENTSPLY SIRONA Inc. by 822.2%, acquiring an additional 18,434 shares for a total of 20,676 shares, valued at approximately $309,000.
• Recent reports from equities analysts indicate that most have set lower price targets for DENTSPLY SIRONA, with Barrington Research reducing its price objective from $21 to $18.
• The company recently announced a quarterly dividend of $0.16 per share, resulting in a dividend yield of 4.7%.

Bayforest Capital Ltd raised its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 822.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,676 shares of the medical instruments supplier's stock after purchasing an additional 18,434 shares during the period. Bayforest Capital Ltd's holdings in DENTSPLY SIRONA were worth $309,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in DENTSPLY SIRONA by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier's stock valued at $8,860,000 after purchasing an additional 41,579 shares in the last quarter. Empowered Funds LLC increased its stake in DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier's stock valued at $244,000 after purchasing an additional 1,320 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock valued at $36,378,000 after purchasing an additional 2,172,343 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in DENTSPLY SIRONA in the first quarter valued at approximately $366,000. Finally, Petrus Trust Company LTA bought a new stake in DENTSPLY SIRONA in the first quarter valued at approximately $167,000. Institutional investors own 95.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Barrington Research lowered their price objective on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Wells Fargo & Company dropped their price objective on shares of DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating on the stock in a report on Friday, August 8th. Stifel Nicolaus dropped their price objective on shares of DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating on the stock in a report on Friday, August 8th. Needham & Company LLC restated a "hold" rating on shares of DENTSPLY SIRONA in a report on Monday, July 21st. Finally, Wall Street Zen lowered shares of DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $18.64.

DENTSPLY SIRONA Stock Performance

Shares of XRAY opened at $13.70 on Thursday. The firm has a 50-day moving average of $14.85 and a 200-day moving average of $15.12. DENTSPLY SIRONA Inc. has a one year low of $12.16 and a one year high of $27.48. The company has a market cap of $2.73 billion, a PE ratio of -2.89, a price-to-earnings-growth ratio of 0.87 and a beta of 0.96. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.69 and a quick ratio of 1.11.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.50 by $0.02. The business had revenue of $936.00 million during the quarter, compared to the consensus estimate of $929.67 million. DENTSPLY SIRONA had a negative net margin of 25.85% and a positive return on equity of 16.33%. DENTSPLY SIRONA's revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.49 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. As a group, equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 10th. Investors of record on Friday, September 26th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $0.64 annualized dividend and a dividend yield of 4.7%. DENTSPLY SIRONA's payout ratio is presently -13.50%.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.